Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKesson
Accenture
McKinsey
Federal Trade Commission
Teva
Cipla
Fish and Richardson
Moodys
Queensland Health

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020314

« Back to Dashboard

NDA 020314 describes OCTREOSCAN, which is a drug marketed by Mallinkrodt Nuclear and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the OCTREOSCAN profile page.

The generic ingredient in OCTREOSCAN is indium in-111 pentetreotide kit. There are twenty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 pentetreotide kit profile page.
Summary for 020314
Tradename:OCTREOSCAN
Applicant:Mallinkrodt Nuclear
Ingredient:indium in-111 pentetreotide kit
Patents:1
Suppliers and Packaging for NDA: 020314
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314 NDA MALLINCKRODT NUCLEAR MEDICINE LLC 69945-050 69945-050-40 1 KIT in 1 BOX (69945-050-40) * 1 mL in 1 VIAL, GLASS * 1 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength3mCi/ML
Approval Date:Jun 2, 1994TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Sep 26, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

Expired US Patents for NDA 020314

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Subscribe ➤ Subscribe
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Subscribe ➤ Subscribe
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Subscribe ➤ Subscribe
Mallinkrodt Nuclear OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Novartis
Merck
Citi
Boehringer Ingelheim
McKesson
Express Scripts
Chinese Patent Office
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot